| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Disease Models, Animal | 40 | 2026 | 2329 | 3.340 |
Why?
|
| CD8-Positive T-Lymphocytes | 40 | 2024 | 679 | 2.970 |
Why?
|
| Mice | 128 | 2026 | 11185 | 2.440 |
Why?
|
| Mice, SCID | 36 | 2023 | 518 | 2.100 |
Why?
|
| Mice, Inbred NOD | 38 | 2025 | 526 | 2.070 |
Why?
|
| Lymphocytic choriomeningitis virus | 18 | 2019 | 88 | 2.030 |
Why?
|
| Graft Rejection | 13 | 2025 | 304 | 1.920 |
Why?
|
| Animals | 140 | 2026 | 21493 | 1.890 |
Why?
|
| Foot Orthoses | 3 | 2025 | 6 | 1.870 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 14 | 2026 | 357 | 1.820 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 15 | 2023 | 81 | 1.810 |
Why?
|
| Hematopoietic Stem Cells | 10 | 2026 | 304 | 1.750 |
Why?
|
| T-Lymphocytes | 13 | 2023 | 1012 | 1.700 |
Why?
|
| Immunologic Memory | 21 | 2025 | 284 | 1.520 |
Why?
|
| Graft vs Host Disease | 7 | 2018 | 113 | 1.500 |
Why?
|
| Diabetes Mellitus, Type 1 | 13 | 2026 | 631 | 1.460 |
Why?
|
| Transplantation, Heterologous | 12 | 2019 | 241 | 1.410 |
Why?
|
| Immune System | 11 | 2023 | 133 | 1.380 |
Why?
|
| Walking | 4 | 2025 | 248 | 1.280 |
Why?
|
| HIV-1 | 6 | 2026 | 710 | 1.030 |
Why?
|
| Salmonella typhi | 5 | 2024 | 19 | 1.010 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2023 | 248 | 1.000 |
Why?
|
| Thymus Gland | 10 | 2024 | 241 | 0.960 |
Why?
|
| fas Receptor | 3 | 2019 | 56 | 0.960 |
Why?
|
| Skin Transplantation | 13 | 2019 | 154 | 0.920 |
Why?
|
| Islets of Langerhans Transplantation | 7 | 2026 | 179 | 0.920 |
Why?
|
| Humans | 103 | 2026 | 65845 | 0.920 |
Why?
|
| Mice, Transgenic | 22 | 2019 | 1292 | 0.920 |
Why?
|
| Typhoid Fever | 5 | 2024 | 21 | 0.900 |
Why?
|
| Mice, Knockout | 27 | 2025 | 2168 | 0.900 |
Why?
|
| Ankle Joint | 2 | 2025 | 48 | 0.900 |
Why?
|
| Stem Cell Factor | 3 | 2016 | 27 | 0.880 |
Why?
|
| Neuromuscular Diseases | 1 | 2025 | 24 | 0.870 |
Why?
|
| Transplantation Tolerance | 6 | 2012 | 69 | 0.860 |
Why?
|
| Immunity, Innate | 7 | 2023 | 829 | 0.850 |
Why?
|
| Neoplasms | 5 | 2025 | 1378 | 0.820 |
Why?
|
| Receptors, Interleukin-2 | 6 | 2015 | 71 | 0.800 |
Why?
|
| Mast Cells | 3 | 2022 | 51 | 0.800 |
Why?
|
| Apoptosis | 7 | 2019 | 1100 | 0.790 |
Why?
|
| Organ Transplantation | 2 | 2015 | 46 | 0.790 |
Why?
|
| Immunotherapy | 6 | 2026 | 274 | 0.780 |
Why?
|
| Walking Speed | 1 | 2023 | 24 | 0.780 |
Why?
|
| Epitopes, T-Lymphocyte | 13 | 2014 | 186 | 0.780 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2023 | 54 | 0.750 |
Why?
|
| Pichinde virus | 7 | 2014 | 20 | 0.750 |
Why?
|
| Mice, Inbred C57BL | 38 | 2026 | 3506 | 0.750 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2011 | 605 | 0.740 |
Why?
|
| Interleukin-15 | 1 | 2022 | 25 | 0.730 |
Why?
|
| Islets of Langerhans | 6 | 2026 | 286 | 0.730 |
Why?
|
| Toll-Like Receptor 4 | 4 | 2023 | 351 | 0.730 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2017 | 223 | 0.710 |
Why?
|
| Flow Cytometry | 12 | 2019 | 664 | 0.700 |
Why?
|
| HIV Infections | 6 | 2026 | 961 | 0.670 |
Why?
|
| Lymphocyte Activation | 13 | 2020 | 755 | 0.650 |
Why?
|
| Communicable Diseases | 4 | 2016 | 86 | 0.640 |
Why?
|
| Arenaviridae Infections | 4 | 2019 | 15 | 0.630 |
Why?
|
| Inflammation | 5 | 2023 | 1198 | 0.610 |
Why?
|
| Epstein-Barr Virus Infections | 3 | 2023 | 105 | 0.610 |
Why?
|
| Anaphylaxis | 2 | 2019 | 41 | 0.610 |
Why?
|
| Neoplasm Transplantation | 2 | 2019 | 167 | 0.590 |
Why?
|
| Homeostasis | 4 | 2019 | 383 | 0.590 |
Why?
|
| Pluripotent Stem Cells | 5 | 2023 | 72 | 0.590 |
Why?
|
| Antigens, Viral | 8 | 2010 | 130 | 0.580 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2019 | 20 | 0.580 |
Why?
|
| Immune System Diseases | 1 | 2019 | 20 | 0.570 |
Why?
|
| Interleukin-2 | 3 | 2023 | 168 | 0.570 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2024 | 49 | 0.560 |
Why?
|
| Major Histocompatibility Complex | 3 | 2014 | 85 | 0.560 |
Why?
|
| Insulin-Secreting Cells | 6 | 2025 | 195 | 0.540 |
Why?
|
| CD4-Positive T-Lymphocytes | 9 | 2023 | 642 | 0.530 |
Why?
|
| Transplantation Immunology | 2 | 2015 | 26 | 0.530 |
Why?
|
| B-Lymphocytes | 4 | 2016 | 565 | 0.520 |
Why?
|
| Precision Medicine | 1 | 2019 | 134 | 0.520 |
Why?
|
| Toll-Like Receptors | 4 | 2013 | 434 | 0.510 |
Why?
|
| Mice, Inbred BALB C | 13 | 2019 | 869 | 0.500 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2016 | 282 | 0.500 |
Why?
|
| Virus Diseases | 5 | 2007 | 118 | 0.500 |
Why?
|
| Cell Differentiation | 9 | 2023 | 1391 | 0.490 |
Why?
|
| Interleukin-3 | 1 | 2016 | 20 | 0.490 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 74 | 0.480 |
Why?
|
| Passive Cutaneous Anaphylaxis | 1 | 2016 | 6 | 0.480 |
Why?
|
| Genetic Therapy | 4 | 2017 | 852 | 0.470 |
Why?
|
| Dependovirus | 3 | 2017 | 760 | 0.470 |
Why?
|
| Ankle | 3 | 2025 | 27 | 0.460 |
Why?
|
| Transplantation, Homologous | 8 | 2026 | 250 | 0.460 |
Why?
|
| Signal Transduction | 14 | 2024 | 3170 | 0.450 |
Why?
|
| Killer Cells, Natural | 5 | 2023 | 220 | 0.440 |
Why?
|
| Transplantation Chimera | 3 | 2012 | 41 | 0.440 |
Why?
|
| Gene Expression | 2 | 2017 | 856 | 0.440 |
Why?
|
| Cell Proliferation | 5 | 2024 | 1044 | 0.440 |
Why?
|
| Antigens, CD | 5 | 2022 | 344 | 0.440 |
Why?
|
| Immunity, Heterologous | 1 | 2014 | 11 | 0.420 |
Why?
|
| Mutation | 6 | 2017 | 2675 | 0.410 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2024 | 234 | 0.410 |
Why?
|
| Adoptive Transfer | 9 | 2023 | 145 | 0.400 |
Why?
|
| CD4 Antigens | 2 | 2013 | 149 | 0.400 |
Why?
|
| Fas Ligand Protein | 2 | 2013 | 40 | 0.400 |
Why?
|
| Herpesvirus 4, Human | 2 | 2023 | 199 | 0.400 |
Why?
|
| Cytokines | 8 | 2023 | 965 | 0.380 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2013 | 46 | 0.380 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2013 | 129 | 0.380 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2001 | 169 | 0.370 |
Why?
|
| Male | 36 | 2025 | 31410 | 0.370 |
Why?
|
| Isoantigens | 6 | 2011 | 72 | 0.370 |
Why?
|
| Immune Tolerance | 7 | 2026 | 187 | 0.360 |
Why?
|
| Blood Glucose | 4 | 2025 | 502 | 0.360 |
Why?
|
| Autoimmunity | 5 | 2026 | 250 | 0.360 |
Why?
|
| Cell Line, Tumor | 14 | 2026 | 1573 | 0.360 |
Why?
|
| Spleen | 6 | 2015 | 476 | 0.360 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 256 | 0.360 |
Why?
|
| RNA, Messenger | 5 | 2026 | 1583 | 0.360 |
Why?
|
| Exercise Test | 1 | 2013 | 257 | 0.360 |
Why?
|
| Lymphocytic Choriomeningitis | 9 | 2014 | 52 | 0.350 |
Why?
|
| Neoplastic Stem Cells | 4 | 2024 | 196 | 0.350 |
Why?
|
| Cross Reactions | 10 | 2014 | 140 | 0.340 |
Why?
|
| Nanoparticles | 3 | 2026 | 553 | 0.330 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2024 | 64 | 0.330 |
Why?
|
| Energy Metabolism | 1 | 2013 | 400 | 0.330 |
Why?
|
| Models, Animal | 4 | 2021 | 243 | 0.320 |
Why?
|
| Interferon-gamma | 10 | 2019 | 576 | 0.320 |
Why?
|
| Disease | 1 | 2010 | 26 | 0.310 |
Why?
|
| Genes, MHC Class II | 3 | 2018 | 36 | 0.310 |
Why?
|
| Heterografts | 4 | 2018 | 67 | 0.300 |
Why?
|
| Viral Proteins | 5 | 2010 | 273 | 0.300 |
Why?
|
| Immunoglobulin G | 3 | 2025 | 472 | 0.290 |
Why?
|
| Cell Line | 13 | 2016 | 2031 | 0.290 |
Why?
|
| Cells, Cultured | 12 | 2025 | 2194 | 0.290 |
Why?
|
| Hyperglycemia | 4 | 2014 | 109 | 0.290 |
Why?
|
| Biomechanical Phenomena | 3 | 2025 | 296 | 0.280 |
Why?
|
| Genes, MHC Class I | 3 | 2018 | 26 | 0.280 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 2019 | 29 | 0.270 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2020 | 138 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 7 | 2025 | 875 | 0.270 |
Why?
|
| H-2 Antigens | 6 | 2010 | 63 | 0.260 |
Why?
|
| Herpesvirus 1, Human | 2 | 1999 | 83 | 0.260 |
Why?
|
| Receptors, IgG | 2 | 2025 | 41 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 218 | 0.260 |
Why?
|
| Graft Survival | 5 | 2018 | 300 | 0.260 |
Why?
|
| Nephrology | 1 | 2007 | 16 | 0.260 |
Why?
|
| Immunodominant Epitopes | 4 | 2010 | 59 | 0.260 |
Why?
|
| Mice, Inbred CBA | 6 | 2007 | 80 | 0.260 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2003 | 241 | 0.250 |
Why?
|
| Neuropilin-2 | 2 | 2024 | 40 | 0.250 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 2005 | 27 | 0.250 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2026 | 26 | 0.240 |
Why?
|
| Female | 24 | 2026 | 34425 | 0.240 |
Why?
|
| Hepatocytes | 3 | 2017 | 226 | 0.240 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2026 | 60 | 0.240 |
Why?
|
| Neuroblastoma | 1 | 2026 | 54 | 0.230 |
Why?
|
| Kidney Diseases | 1 | 2007 | 178 | 0.230 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 79 | 0.230 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2019 | 70 | 0.230 |
Why?
|
| Vaccination | 2 | 2026 | 388 | 0.220 |
Why?
|
| Autoantigens | 1 | 2026 | 140 | 0.220 |
Why?
|
| Interferon Regulatory Factors | 2 | 2015 | 43 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2024 | 23 | 0.220 |
Why?
|
| Chromosome Inversion | 1 | 2024 | 19 | 0.220 |
Why?
|
| Neuropilin-1 | 1 | 2024 | 13 | 0.220 |
Why?
|
| Interferon Regulatory Factor-2 | 1 | 2024 | 5 | 0.220 |
Why?
|
| Organoids | 1 | 2025 | 44 | 0.220 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2024 | 34 | 0.210 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2024 | 22 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 645 | 0.210 |
Why?
|
| Lipopolysaccharides | 6 | 2019 | 625 | 0.210 |
Why?
|
| LIM Domain Proteins | 1 | 2024 | 32 | 0.200 |
Why?
|
| Immunoglobulin M | 2 | 2014 | 116 | 0.200 |
Why?
|
| Transient Receptor Potential Channels | 1 | 2023 | 10 | 0.200 |
Why?
|
| Immunity, Cellular | 2 | 2018 | 170 | 0.200 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 71 | 0.200 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2023 | 8 | 0.200 |
Why?
|
| Nitric Oxide | 1 | 2024 | 165 | 0.200 |
Why?
|
| Pharynx | 1 | 2023 | 25 | 0.200 |
Why?
|
| Salmonella | 1 | 2024 | 45 | 0.200 |
Why?
|
| Liver | 6 | 2023 | 875 | 0.200 |
Why?
|
| Gait | 2 | 2023 | 124 | 0.200 |
Why?
|
| Vaccinia | 4 | 2010 | 29 | 0.190 |
Why?
|
| Vaccinia virus | 4 | 2010 | 69 | 0.190 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 310 | 0.190 |
Why?
|
| Dengue Virus | 2 | 2014 | 101 | 0.190 |
Why?
|
| Fatigue | 1 | 2023 | 114 | 0.190 |
Why?
|
| Foreign Bodies | 1 | 2023 | 56 | 0.190 |
Why?
|
| Autoimmune Diseases | 2 | 2019 | 240 | 0.190 |
Why?
|
| Muscles | 1 | 2023 | 179 | 0.180 |
Why?
|
| Mice, Mutant Strains | 2 | 2014 | 301 | 0.180 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2024 | 441 | 0.180 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 77 | 0.180 |
Why?
|
| Oxidative Stress | 1 | 2024 | 323 | 0.180 |
Why?
|
| Kidney | 1 | 2025 | 460 | 0.180 |
Why?
|
| Biomedical Research | 1 | 2025 | 263 | 0.180 |
Why?
|
| Kidney Transplantation | 1 | 2025 | 326 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 193 | 0.180 |
Why?
|
| Animals, Newborn | 3 | 2012 | 241 | 0.180 |
Why?
|
| Burkitt Lymphoma | 1 | 2023 | 74 | 0.180 |
Why?
|
| Biocompatible Materials | 1 | 2023 | 154 | 0.180 |
Why?
|
| Cell Transplantation | 2 | 2019 | 41 | 0.170 |
Why?
|
| Genetic Vectors | 3 | 2017 | 930 | 0.170 |
Why?
|
| Chimerism | 3 | 2014 | 12 | 0.170 |
Why?
|
| Adaptive Immunity | 2 | 2013 | 105 | 0.170 |
Why?
|
| Hematopoiesis | 2 | 2014 | 128 | 0.170 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 1635 | 0.170 |
Why?
|
| Second Messenger Systems | 1 | 2021 | 27 | 0.170 |
Why?
|
| Melanoma | 1 | 2024 | 335 | 0.170 |
Why?
|
| Dinoprostone | 1 | 2021 | 42 | 0.160 |
Why?
|
| Injections, Intravenous | 3 | 2016 | 160 | 0.160 |
Why?
|
| Knee Joint | 1 | 2023 | 312 | 0.160 |
Why?
|
| Escherichia coli | 1 | 2025 | 718 | 0.160 |
Why?
|
| Peptides | 5 | 2010 | 593 | 0.160 |
Why?
|
| Brain Neoplasms | 1 | 2024 | 323 | 0.160 |
Why?
|
| Leukocyte Common Antigens | 4 | 2013 | 58 | 0.160 |
Why?
|
| Cyclic AMP | 1 | 2021 | 144 | 0.160 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 94 | 0.160 |
Why?
|
| Lymphocytes | 3 | 2023 | 210 | 0.160 |
Why?
|
| Endodeoxyribonucleases | 1 | 2019 | 44 | 0.150 |
Why?
|
| Bone Marrow Cells | 2 | 2014 | 237 | 0.150 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2019 | 25 | 0.150 |
Why?
|
| Dexamethasone | 1 | 2021 | 214 | 0.150 |
Why?
|
| RNA, Small Interfering | 3 | 2021 | 993 | 0.150 |
Why?
|
| Antigen-Presenting Cells | 3 | 2010 | 180 | 0.150 |
Why?
|
| Thiazolidines | 1 | 2019 | 14 | 0.150 |
Why?
|
| Lectins | 1 | 2019 | 43 | 0.150 |
Why?
|
| Biphenyl Compounds | 1 | 2019 | 29 | 0.150 |
Why?
|
| Salmonella Infections | 1 | 2019 | 42 | 0.150 |
Why?
|
| Eosinophils | 1 | 2019 | 51 | 0.150 |
Why?
|
| Th1 Cells | 1 | 2019 | 171 | 0.140 |
Why?
|
| Insulin | 3 | 2025 | 697 | 0.140 |
Why?
|
| Phenotype | 3 | 2018 | 1236 | 0.140 |
Why?
|
| Immediate-Early Proteins | 1 | 1999 | 46 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2006 | 922 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 39 | 0.140 |
Why?
|
| Prostatic Neoplasms | 1 | 2023 | 504 | 0.140 |
Why?
|
| CD40 Ligand | 4 | 2013 | 159 | 0.140 |
Why?
|
| Immunity | 1 | 2019 | 107 | 0.130 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2018 | 130 | 0.130 |
Why?
|
| Rituximab | 3 | 2025 | 89 | 0.130 |
Why?
|
| HIV Antibodies | 1 | 2018 | 146 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 366 | 0.130 |
Why?
|
| Cricetinae | 6 | 2015 | 362 | 0.130 |
Why?
|
| Transplantation Conditioning | 1 | 2017 | 101 | 0.130 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 344 | 0.130 |
Why?
|
| Biomarkers | 1 | 2023 | 1503 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2017 | 58 | 0.130 |
Why?
|
| von Willebrand Disease, Type 2 | 1 | 2016 | 1 | 0.120 |
Why?
|
| beta-Thalassemia | 1 | 2016 | 15 | 0.120 |
Why?
|
| Peptide Nucleic Acids | 1 | 2016 | 17 | 0.120 |
Why?
|
| von Willebrand Factor | 1 | 2016 | 10 | 0.120 |
Why?
|
| Transgenes | 1 | 2017 | 207 | 0.120 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2017 | 91 | 0.120 |
Why?
|
| Complement System Proteins | 1 | 2017 | 110 | 0.120 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2017 | 70 | 0.120 |
Why?
|
| Liver Transplantation | 2 | 2016 | 222 | 0.120 |
Why?
|
| HLA-DR4 Antigen | 2 | 2016 | 9 | 0.120 |
Why?
|
| Radiation Chimera | 3 | 2021 | 61 | 0.120 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2016 | 46 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2014 | 113 | 0.120 |
Why?
|
| T-Box Domain Proteins | 1 | 2015 | 38 | 0.120 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 1 | 1 | 2015 | 6 | 0.120 |
Why?
|
| Retroviridae Infections | 1 | 2015 | 13 | 0.120 |
Why?
|
| Hepatitis | 1 | 2016 | 58 | 0.120 |
Why?
|
| Alopecia Areata | 1 | 2015 | 10 | 0.120 |
Why?
|
| Immunoglobulin E | 1 | 2016 | 81 | 0.120 |
Why?
|
| Homeodomain Proteins | 3 | 2013 | 277 | 0.120 |
Why?
|
| Young Adult | 2 | 2025 | 4883 | 0.120 |
Why?
|
| Leukemia Virus, Murine | 1 | 2015 | 29 | 0.120 |
Why?
|
| CD3 Complex | 2 | 2014 | 63 | 0.110 |
Why?
|
| Gene Editing | 2 | 2017 | 331 | 0.110 |
Why?
|
| Virus Replication | 1 | 1997 | 323 | 0.110 |
Why?
|
| Glucose | 2 | 2010 | 478 | 0.110 |
Why?
|
| Myeloid Cells | 1 | 2016 | 98 | 0.110 |
Why?
|
| Lymphocyte Count | 2 | 2013 | 71 | 0.110 |
Why?
|
| Immunocompromised Host | 2 | 2011 | 104 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 588 | 0.110 |
Why?
|
| Epitopes | 5 | 2022 | 291 | 0.110 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 113 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2016 | 105 | 0.110 |
Why?
|
| Antibodies, Viral | 2 | 2014 | 329 | 0.110 |
Why?
|
| Oxygen Consumption | 1 | 2016 | 213 | 0.110 |
Why?
|
| Cell Movement | 1 | 2017 | 484 | 0.110 |
Why?
|
| Poly I-C | 7 | 2013 | 76 | 0.110 |
Why?
|
| Glucose Intolerance | 1 | 2016 | 90 | 0.110 |
Why?
|
| Models, Biological | 1 | 2020 | 1193 | 0.110 |
Why?
|
| Molecular Sequence Data | 3 | 2015 | 1980 | 0.110 |
Why?
|
| Nuclear Proteins | 3 | 2014 | 793 | 0.110 |
Why?
|
| Coxsackievirus Infections | 1 | 2014 | 12 | 0.110 |
Why?
|
| Virus Internalization | 1 | 2015 | 91 | 0.110 |
Why?
|
| Chromatin | 2 | 2023 | 643 | 0.110 |
Why?
|
| Cross Protection | 1 | 2014 | 6 | 0.110 |
Why?
|
| Interferon Type I | 3 | 2019 | 198 | 0.110 |
Why?
|
| Tissue Transplantation | 1 | 2014 | 9 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 175 | 0.100 |
Why?
|
| Receptor, Interferon alpha-beta | 3 | 2009 | 54 | 0.100 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2014 | 63 | 0.100 |
Why?
|
| Salicylates | 1 | 2013 | 9 | 0.100 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 242 | 0.100 |
Why?
|
| Tumor Microenvironment | 2 | 2026 | 183 | 0.100 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 44 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2014 | 76 | 0.100 |
Why?
|
| Mycobacterium bovis | 1 | 2013 | 29 | 0.100 |
Why?
|
| Middle Aged | 4 | 2025 | 18501 | 0.100 |
Why?
|
| Herpes Simplex | 3 | 1999 | 49 | 0.100 |
Why?
|
| Macrophages | 5 | 2024 | 1042 | 0.100 |
Why?
|
| Fetus | 1 | 2014 | 103 | 0.100 |
Why?
|
| Virulence | 3 | 2022 | 199 | 0.100 |
Why?
|
| Adipocytes | 1 | 2016 | 276 | 0.100 |
Why?
|
| HLA Antigens | 3 | 2025 | 62 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 24 | 0.100 |
Why?
|
| Mice, Inbred C3H | 4 | 2008 | 173 | 0.100 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2013 | 111 | 0.100 |
Why?
|
| Small Molecule Libraries | 1 | 2013 | 57 | 0.090 |
Why?
|
| Gallbladder | 1 | 2013 | 40 | 0.090 |
Why?
|
| Endoplasmic Reticulum | 2 | 2016 | 180 | 0.090 |
Why?
|
| Influenza A virus | 1 | 2014 | 122 | 0.090 |
Why?
|
| Lectins, C-Type | 1 | 2013 | 80 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 205 | 0.090 |
Why?
|
| Retrospective Studies | 1 | 2025 | 6957 | 0.090 |
Why?
|
| Antibodies | 1 | 2013 | 188 | 0.090 |
Why?
|
| HLA-A2 Antigen | 1 | 2012 | 62 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2012 | 64 | 0.090 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2011 | 2 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2014 | 372 | 0.090 |
Why?
|
| Fibrosis | 2 | 2023 | 172 | 0.090 |
Why?
|
| Viruses | 2 | 2010 | 82 | 0.090 |
Why?
|
| Specific Pathogen-Free Organisms | 2 | 2010 | 42 | 0.090 |
Why?
|
| Cell Separation | 1 | 2012 | 147 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2014 | 1561 | 0.090 |
Why?
|
| Dendritic Cells | 3 | 2026 | 534 | 0.080 |
Why?
|
| Child | 3 | 2021 | 4653 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2024 | 286 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 211 | 0.080 |
Why?
|
| Adult | 3 | 2025 | 17579 | 0.080 |
Why?
|
| Prognosis | 1 | 2015 | 1793 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2013 | 414 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 2 | 2009 | 140 | 0.080 |
Why?
|
| Mice, Obese | 2 | 2021 | 80 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 408 | 0.080 |
Why?
|
| Crosses, Genetic | 1 | 2010 | 116 | 0.080 |
Why?
|
| Histocytochemistry | 1 | 2010 | 48 | 0.080 |
Why?
|
| Embryo, Nonmammalian | 1 | 2010 | 184 | 0.080 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2025 | 160 | 0.080 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 382 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2013 | 314 | 0.080 |
Why?
|
| Cell Survival | 3 | 2009 | 588 | 0.080 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2010 | 42 | 0.080 |
Why?
|
| Nucleoproteins | 3 | 2006 | 32 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 213 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 542 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 129 | 0.070 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2009 | 81 | 0.070 |
Why?
|
| Transcription Factor CHOP | 1 | 2009 | 8 | 0.070 |
Why?
|
| Antibodies, Neutralizing | 3 | 2018 | 220 | 0.070 |
Why?
|
| Rats | 4 | 2015 | 2005 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 1 | 2009 | 132 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 203 | 0.070 |
Why?
|
| GTP-Binding Proteins | 1 | 2009 | 93 | 0.070 |
Why?
|
| Coculture Techniques | 3 | 2017 | 104 | 0.070 |
Why?
|
| Peptide Fragments | 3 | 2016 | 419 | 0.070 |
Why?
|
| Models, Immunological | 3 | 2011 | 85 | 0.070 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 325 | 0.070 |
Why?
|
| Lymph Nodes | 3 | 2015 | 237 | 0.060 |
Why?
|
| Zebrafish | 1 | 2010 | 374 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2009 | 210 | 0.060 |
Why?
|
| Molluscum contagiosum virus | 1 | 2006 | 1 | 0.060 |
Why?
|
| Molecular Mimicry | 1 | 2006 | 31 | 0.060 |
Why?
|
| Ligands | 2 | 2005 | 414 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2016 | 152 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 38 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 558 | 0.060 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2006 | 10 | 0.060 |
Why?
|
| Aminopeptidases | 1 | 2006 | 26 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 24 | 0.060 |
Why?
|
| Population Dynamics | 1 | 2025 | 21 | 0.060 |
Why?
|
| Leukocytes | 1 | 2006 | 110 | 0.060 |
Why?
|
| Liposomes | 1 | 2026 | 118 | 0.060 |
Why?
|
| Time Factors | 3 | 2010 | 3779 | 0.060 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2005 | 11 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 128 | 0.060 |
Why?
|
| Cell Line, Transformed | 1 | 2005 | 97 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2025 | 20 | 0.060 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2025 | 1 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2006 | 102 | 0.060 |
Why?
|
| Half-Life | 1 | 2025 | 81 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 128 | 0.060 |
Why?
|
| Lung | 3 | 2013 | 969 | 0.060 |
Why?
|
| Allografts | 1 | 2025 | 47 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 196 | 0.060 |
Why?
|
| Remission Induction | 1 | 2025 | 149 | 0.050 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2024 | 9 | 0.050 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 1226 | 0.050 |
Why?
|
| Viral Vaccines | 2 | 2010 | 56 | 0.050 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2024 | 12 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 233 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 738 | 0.050 |
Why?
|
| Melanoma, Experimental | 1 | 2024 | 43 | 0.050 |
Why?
|
| Animals, Genetically Modified | 2 | 2018 | 312 | 0.050 |
Why?
|
| Radiation Tolerance | 1 | 2024 | 56 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2024 | 61 | 0.050 |
Why?
|
| Stem Cells | 1 | 2026 | 278 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2024 | 64 | 0.050 |
Why?
|
| Oxygen | 1 | 2006 | 323 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2024 | 18 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2006 | 284 | 0.050 |
Why?
|
| TRPC Cation Channels | 1 | 2023 | 14 | 0.050 |
Why?
|
| TRPC6 Cation Channel | 1 | 2023 | 8 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2024 | 34 | 0.050 |
Why?
|
| Integrin alpha6 | 1 | 2023 | 20 | 0.050 |
Why?
|
| Digestive System | 1 | 2023 | 26 | 0.050 |
Why?
|
| Myocardium | 1 | 2006 | 302 | 0.050 |
Why?
|
| Immunization | 3 | 2001 | 135 | 0.050 |
Why?
|
| Lipids | 1 | 2026 | 331 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2023 | 5834 | 0.050 |
Why?
|
| Organ Specificity | 4 | 2006 | 201 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2024 | 55 | 0.050 |
Why?
|
| Foreign-Body Reaction | 1 | 2023 | 16 | 0.050 |
Why?
|
| Endoderm | 1 | 2023 | 47 | 0.050 |
Why?
|
| Amino Acid Sequence | 4 | 2015 | 1590 | 0.050 |
Why?
|
| Lymphoid Tissue | 1 | 2003 | 54 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2003 | 84 | 0.050 |
Why?
|
| Microbiota | 1 | 2025 | 171 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2023 | 109 | 0.050 |
Why?
|
| Dengue | 2 | 2014 | 98 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2023 | 69 | 0.050 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2022 | 4 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2025 | 226 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 449 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 60 | 0.050 |
Why?
|
| Research Personnel | 1 | 2023 | 82 | 0.050 |
Why?
|
| Gene Silencing | 2 | 2017 | 439 | 0.050 |
Why?
|
| Bystander Effect | 1 | 2002 | 6 | 0.050 |
Why?
|
| Viral Load | 2 | 2014 | 230 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 426 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2003 | 112 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2024 | 436 | 0.040 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2023 | 179 | 0.040 |
Why?
|
| Diacylglycerol O-Acyltransferase | 1 | 2021 | 11 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2001 | 17 | 0.040 |
Why?
|
| RNAi Therapeutics | 1 | 2021 | 12 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2015 | 372 | 0.040 |
Why?
|
| Viral Envelope Proteins | 2 | 1999 | 102 | 0.040 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2021 | 5 | 0.040 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 2021 | 12 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2021 | 12 | 0.040 |
Why?
|
| Colforsin | 1 | 2021 | 25 | 0.040 |
Why?
|
| Chromogranins | 1 | 2021 | 12 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 2021 | 33 | 0.040 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2021 | 28 | 0.040 |
Why?
|
| Interferon-beta | 1 | 2001 | 79 | 0.040 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2021 | 52 | 0.040 |
Why?
|
| Interferon-alpha | 1 | 2001 | 101 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2001 | 90 | 0.040 |
Why?
|
| Obesity | 2 | 2021 | 1281 | 0.040 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2020 | 26 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2002 | 398 | 0.040 |
Why?
|
| Antigen Presentation | 2 | 1999 | 239 | 0.040 |
Why?
|
| Calcium | 1 | 2023 | 587 | 0.040 |
Why?
|
| Triglycerides | 1 | 2021 | 249 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 53 | 0.040 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2019 | 12 | 0.040 |
Why?
|
| Genomic Islands | 1 | 2019 | 8 | 0.040 |
Why?
|
| Amino Acids, Aromatic | 1 | 2019 | 7 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2023 | 663 | 0.040 |
Why?
|
| Basophils | 1 | 2019 | 15 | 0.040 |
Why?
|
| Siderophores | 1 | 2019 | 12 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2019 | 23 | 0.040 |
Why?
|
| Mice, Congenic | 2 | 2010 | 22 | 0.040 |
Why?
|
| bcl-Associated Death Protein | 1 | 2019 | 10 | 0.040 |
Why?
|
| Leukemia, Experimental | 1 | 2019 | 19 | 0.040 |
Why?
|
| Ribonucleotide Reductases | 1 | 1999 | 4 | 0.040 |
Why?
|
| Imatinib Mesylate | 1 | 2019 | 34 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2019 | 17 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 44 | 0.040 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2019 | 35 | 0.040 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 1999 | 21 | 0.040 |
Why?
|
| Genes, Viral | 1 | 1999 | 57 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1999 | 49 | 0.040 |
Why?
|
| Bacterial Toxins | 1 | 2019 | 58 | 0.040 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2019 | 48 | 0.040 |
Why?
|
| Herpesvirus 2, Human | 1 | 1998 | 14 | 0.040 |
Why?
|
| Mutagenesis | 1 | 1999 | 133 | 0.040 |
Why?
|
| Neutralization Tests | 1 | 2018 | 126 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 1999 | 129 | 0.040 |
Why?
|
| Iron | 1 | 2019 | 156 | 0.030 |
Why?
|
| Toll-Like Receptor 3 | 2 | 2008 | 66 | 0.030 |
Why?
|
| Antigens | 1 | 1998 | 145 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2009 | 203 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 198 | 0.030 |
Why?
|
| Simplexvirus | 1 | 1997 | 26 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2017 | 4 | 0.030 |
Why?
|
| E-Selectin | 1 | 2017 | 19 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2017 | 13 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 1999 | 229 | 0.030 |
Why?
|
| RNA Interference | 1 | 2021 | 647 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 466 | 0.030 |
Why?
|
| beta-Globins | 1 | 2016 | 10 | 0.030 |
Why?
|
| Glycosylation | 1 | 2017 | 139 | 0.030 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2016 | 6 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 32 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 2012 | 103 | 0.030 |
Why?
|
| Glutamate Decarboxylase | 1 | 2016 | 21 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 2016 | 56 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 963 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2016 | 51 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2017 | 103 | 0.030 |
Why?
|
| Proprotein Convertase 1 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Leukocyte Transfusion | 2 | 2010 | 16 | 0.030 |
Why?
|
| Enkephalins | 1 | 2016 | 20 | 0.030 |
Why?
|
| Interleukin-33 | 1 | 2016 | 19 | 0.030 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2016 | 19 | 0.030 |
Why?
|
| Iodide Peroxidase | 1 | 2016 | 23 | 0.030 |
Why?
|
| Glucose Clamp Technique | 1 | 2016 | 57 | 0.030 |
Why?
|
| Capillaries | 1 | 2016 | 35 | 0.030 |
Why?
|
| Integrin beta1 | 1 | 2016 | 32 | 0.030 |
Why?
|
| Uncoupling Protein 1 | 1 | 2016 | 51 | 0.030 |
Why?
|
| Adipocytes, White | 1 | 2016 | 27 | 0.030 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2015 | 7 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2016 | 97 | 0.030 |
Why?
|
| Protein Conformation | 1 | 1998 | 793 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2016 | 136 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2016 | 85 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 233 | 0.030 |
Why?
|
| Adipocytes, Brown | 1 | 2016 | 46 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 789 | 0.030 |
Why?
|
| Ion Channels | 1 | 2016 | 92 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2016 | 114 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 110 | 0.030 |
Why?
|
| Enterovirus B, Human | 1 | 2014 | 17 | 0.030 |
Why?
|
| Whole-Body Irradiation | 2 | 2009 | 34 | 0.030 |
Why?
|
| Interferon Inducers | 2 | 2007 | 11 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 181 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 47 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2015 | 263 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 514 | 0.030 |
Why?
|
| Capsid Proteins | 1 | 2015 | 107 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 676 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2016 | 710 | 0.030 |
Why?
|
| Azepines | 1 | 2014 | 22 | 0.030 |
Why?
|
| Annexin A5 | 2 | 2004 | 20 | 0.030 |
Why?
|
| Hydrolases | 1 | 2014 | 84 | 0.030 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 741 | 0.030 |
Why?
|
| Parvovirus | 1 | 2013 | 25 | 0.030 |
Why?
|
| Triazoles | 1 | 2014 | 63 | 0.020 |
Why?
|
| Receptor, Notch1 | 1 | 2014 | 67 | 0.020 |
Why?
|
| Thyroid Nuclear Factor 1 | 1 | 2013 | 4 | 0.020 |
Why?
|
| PAX9 Transcription Factor | 1 | 2013 | 3 | 0.020 |
Why?
|
| Indoles | 1 | 2014 | 112 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2013 | 8 | 0.020 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2013 | 23 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2019 | 926 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2014 | 208 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 146 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 211 | 0.020 |
Why?
|
| Culture Media | 1 | 2013 | 78 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 377 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 1997 | 475 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2013 | 59 | 0.020 |
Why?
|
| Vagina | 1 | 2013 | 87 | 0.020 |
Why?
|
| Genes, abl | 1 | 2012 | 9 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2012 | 17 | 0.020 |
Why?
|
| PAX5 Transcription Factor | 1 | 2012 | 13 | 0.020 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2012 | 12 | 0.020 |
Why?
|
| Dengue Vaccines | 1 | 2012 | 8 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 32 | 0.020 |
Why?
|
| K562 Cells | 1 | 2012 | 59 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 899 | 0.020 |
Why?
|
| Acute Disease | 1 | 2014 | 665 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2012 | 40 | 0.020 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 154 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 626 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2013 | 282 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 665 | 0.020 |
Why?
|
| Regenerative Medicine | 1 | 2011 | 22 | 0.020 |
Why?
|
| United States | 1 | 2025 | 8189 | 0.020 |
Why?
|
| DNA | 1 | 2016 | 853 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2014 | 404 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 279 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2011 | 179 | 0.020 |
Why?
|
| Membrane Glycoproteins | 2 | 2006 | 667 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2012 | 267 | 0.020 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 2010 | 5 | 0.020 |
Why?
|
| Picolinic Acids | 1 | 2010 | 7 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2017 | 714 | 0.020 |
Why?
|
| Histones | 1 | 2014 | 497 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 321 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2010 | 213 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2010 | 103 | 0.020 |
Why?
|
| Proteins | 1 | 2016 | 764 | 0.020 |
Why?
|
| beta 2-Microglobulin | 1 | 2010 | 49 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 1332 | 0.020 |
Why?
|
| Aged | 2 | 2016 | 15147 | 0.020 |
Why?
|
| Gap Junctions | 1 | 2009 | 18 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 408 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2009 | 35 | 0.020 |
Why?
|
| Etanercept | 1 | 2009 | 33 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2010 | 142 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2009 | 64 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2010 | 147 | 0.020 |
Why?
|
| Phylogeny | 1 | 2010 | 400 | 0.020 |
Why?
|
| Cell Communication | 1 | 2009 | 135 | 0.020 |
Why?
|
| Models, Molecular | 2 | 2006 | 1161 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 71 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2009 | 292 | 0.020 |
Why?
|
| Wound Healing | 1 | 2010 | 193 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2009 | 100 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 206 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2009 | 206 | 0.020 |
Why?
|
| Influenza, Human | 1 | 2010 | 213 | 0.020 |
Why?
|
| Hemocyanins | 1 | 2006 | 24 | 0.020 |
Why?
|
| Tumor Necrosis Factors | 1 | 2006 | 8 | 0.020 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2006 | 10 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 2006 | 96 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 37 | 0.020 |
Why?
|
| Vero Cells | 1 | 2006 | 81 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2006 | 36 | 0.010 |
Why?
|
| Receptors, Interleukin-12 | 1 | 2006 | 9 | 0.010 |
Why?
|
| Clonal Deletion | 1 | 2006 | 13 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2006 | 29 | 0.010 |
Why?
|
| Receptors, Interleukin | 1 | 2006 | 38 | 0.010 |
Why?
|
| Necrosis | 1 | 2006 | 147 | 0.010 |
Why?
|
| Mathematical Computing | 1 | 2004 | 12 | 0.010 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2004 | 16 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2004 | 34 | 0.010 |
Why?
|
| Nucleocapsid Proteins | 1 | 2004 | 34 | 0.010 |
Why?
|
| Viral Core Proteins | 1 | 2004 | 28 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2009 | 719 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 2004 | 97 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 194 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2006 | 423 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2004 | 189 | 0.010 |
Why?
|
| Succinimides | 1 | 2002 | 17 | 0.010 |
Why?
|
| Fluoresceins | 1 | 2002 | 31 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2001 | 29 | 0.010 |
Why?
|
| Perforin | 1 | 2001 | 26 | 0.010 |
Why?
|
| Hyaluronan Receptors | 1 | 2001 | 35 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2001 | 34 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 451 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 204 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 2000 | 53 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2000 | 375 | 0.010 |
Why?
|
| Herpes Genitalis | 1 | 1998 | 3 | 0.010 |
Why?
|
| Adolescent | 1 | 2010 | 6368 | 0.010 |
Why?
|
| Peptide Library | 1 | 1998 | 33 | 0.010 |
Why?
|
| Immunity, Mucosal | 1 | 1998 | 53 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1998 | 143 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1998 | 357 | 0.010 |
Why?
|
| Foot | 1 | 1997 | 42 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1998 | 256 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1997 | 111 | 0.010 |
Why?
|
| Restraint, Physical | 1 | 1997 | 58 | 0.010 |
Why?
|
| Central Nervous System | 1 | 1998 | 205 | 0.010 |
Why?
|
| Protein Binding | 1 | 1998 | 1638 | 0.010 |
Why?
|